Re­silience al­lo­cates $225M to ex­pand man­u­fac­tur­ing ca­pac­i­ty in Cincin­nati

Na­tion­al Re­silience is work­ing to ex­pand its clin­i­cal and com­mer­cial drug man­u­fac­tur­ing ca­pa­bil­i­ties to pro­vide more than 200 mil­lion units to its clients by 2025.

Re­silience plans to in­vest at least $225 mil­lion in­to its Cincin­nati site, which is ded­i­cat­ed to fill­ing vials, car­tridges and pre-filled sy­ringes, a com­pa­ny re­lease states. The num­ber of high-speed fill lines should in­crease from three to four by 2025, while the num­ber of de­vice as­sem­bly and pack­ag­ing suites should grow to six.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER